Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Belinostat + Cisplatin + Etoposide |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Belinostat | Beleodaq | PDX101|NSC726630|PX-105684 | HDAC Inhibitor 45 | Beleodaq (belinostat) is an HDAC inhibitor, which promotes tumor cell apoptosis, potentially leading to decreased tumor growth (PMID: 12939461, PMID: 16928830, PMID: 17935615). Beleodaq (belinostat) is FDA approved for patients with relapsed or refractory peripheral T-cell lymphoma (FDA.gov). |
Cisplatin | Platinol | CDDP | Chemotherapy - Platinum 7 | Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary). |
Etoposide | Vepesid | EPEG|Eposin|VP-16|VP-16-213 | TOPO2 inhibitor 5 | Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00926640 | Phase I | Belinostat + Cisplatin + Etoposide | A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers | Completed | USA | 0 |
NCT06406465 | Phase II | Belinostat + Cisplatin + Etoposide | A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity | Not yet recruiting | USA | 0 |